Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: rubiustx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/13/2022 | Buy → Neutral | Guggenheim | |
| 2/25/2022 | $14.00 → $5.00 | Market Perform | SVB Leerink |
| 11/9/2021 | $20.00 → $14.00 | Market Perform | SVB Leerink |
| 10/19/2021 | $25.00 → $22.00 | Equal-Weight | Morgan Stanley |